Loading…
Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Saved in:
Published in: | Blood 2022-11, Vol.140 (Supplement 1), p.2155-2156 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | |
---|---|
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2022-156948 |